Search Results - "Pangallo, B."

Long‐term safety profile of ixekizumab in patients with moderate‐to‐severe plaque psoriasis: an integrated analysis from 11 clinical trials by Langley, R.G., Kimball, A.B., Nak, H., Xu, W., Pangallo, B., Osuntokun, O.O., Agada, N., Reich, K.

“…Background Psoriasis in many patients is a chronic and recalcitrant disease that requires long‐term treatment, reinforcing the importance of long‐term safety…”
Get full text

Prevalence and outcome of latent tuberculosis in patients receiving ixekizumab: integrated safety analysis from 11 clinical trials of patients with plaque psoriasis by Romiti, R., Valenzuela, F., Chouela, E.N., Xu, W., Pangallo, B., Moriarty, S.R., Gürbüz, S., Riedl, E.

Get full text

Phase 3, open‐label, randomized study of the pharmacokinetics, efficacy and safety of ixekizumab following subcutaneous administration using a prefilled syringe or an autoinjector in patients with moderate‐to‐severe plaque psoriasis (UNCOVER‐A) by Callis Duffin, K., Bagel, J., Bukhalo, M., Mercado Clement, I.J., Choi, S.L., Zhao, F., Gill, A., Pangallo, B., Shuler, C., Mallbris, L., Jackson, K.

“…Background The efficacy of ixekizumab, an anti‐interleukin‐17A (anti‐IL‐17A) monoclonal IgG4 antibody, was demonstrated in moderate‐to‐severe psoriasis…”
Get full text

Cardiovascular profile of duloxetine, a dual reuptake inhibitor of serotonin and norepinephrine by THASE, Michael E, TRAN, Pierre V, WILTSE, Curtis, PANGALLO, Beth A, MALLINCKRODT, Craig, DETKE, Michael J

“…This analysis assessed the effects of duloxetine, a dual reuptake inhibitor of serotonin and norepinephrine, on indices of cardiovascular safety, including…”
Get full text

Usability of a novel disposable autoinjector device for ixekizumab: results from a qualitative study and an open-label clinical trial, including patient-reported experience by Callis Duffin, Kristina, Bukhalo, Michael, Bobonich, Margaret A, Shrom, David, Zhao, Fangyi, Kershner, James R, Gill, Anne, Pangallo, Beth, Shuler, Catherine L, Bagel, Jerry

“…Most biologic therapies for psoriasis are delivered via subcutaneous injection. Ixekizumab, an anti-interleukin 17A monoclonal antibody approved for patients…”
Get full text

Ixékizumab et grossesse by Feldman, S.R., Pangallo, B., Xu, W.I., Agada, N., Osuntokun, O., Iversen, L., Schneider, P.

“…Chez les femmes, le psoriasis se manifeste généralement lorsqu’elles sont en âge de procréer. L’ixékizumab (IXE) est un anticorps monoclonal de haute affinité,…”
Get full text

Long-term safety of duloxetine during open-label compassionate use treatment of patients who completed previous duloxetine clinical trials by Pangallo, Beth A., Zhang, Qi, Desaiah, Durisala, Perahia, David G.S., Detke, Michael J., Kennedy, Sidney H.

“…Abstract Purpose: To provide duloxetine for the treatment of major depressive disorder (MDD), generalized anxiety disorder (GAD), fibromyalgia (FM) and…”
Get full text